MediRama, a clinical development research organization (CDRO), said it signed a memorandum of understanding (MOU) with LianBio, a biotech firm, for business cooperation.

The two companies plan to collaborate for clinical development in Korea and Asia, licensing substances developed by HK Biotec and evaluating LianBio products’ potential in the Korean market.

LianBio, based in New Jersey in the U.S. and Shanghai in China, provides transformative medicines to Asia, including China, by collaborating with biopharmaceutical companies in the U.S. and Europe, according to MediRama.

LianBio operates various clinical programs for anticancer, cardiovascular, ophthalmic disease, and autoimmune disease medicines.

Moon Han-lim, CEO of MediRama, said she was pleased to have an opportunity to participate in clinical development in Asia in partnership with LianBio.

“With the partnership, we will also broaden the scope of cooperation with U.S. biotech companies,” Moon said.